← Leaderboards
Mary Lynn Trawick
Baylor University
$1,336,392
Attributed
$3,305,490
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $490K · FY2010–23$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,305,490 · 2
By mechanism
R01$3,305,490 · 2
Top collaborators
- Kevin G Pinney9 shared
- Rolf A Brekken4 shared
Others in their field
Top investigators on “Prodrugs”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Robert Turner Schooley · University Of Colorado Denver$47,231,917
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$26,039,397
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Kevin V Grimes · Stanford University$14,783,804
Research focus
ProdrugsMammary NeoplasmsNecrosisNeoplastic CellInnovationMalignant NeoplasmsDrug KineticsCellsMediatingCytotoxicityEvaluationGrowthAnalogIn VivoAntineoplastic AgentsCharacteristicsBlood VesselsBreast Cancer CellAntibodiesDesignChemical SynthesisClinically RelevantEndothelial CellsSignal Transduction
Grant awards (9)
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2023 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2022 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$475,608
R01 · FY2021 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$490,013
R01 · FY2020 · CA
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$274,502
R01 · FY2014 · CA
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$266,013
R01 · FY2013 · CA
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$282,992
R01 · FY2012 · CA
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$282,992
R01 · FY2011 · CA
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$300,870
R01 · FY2010 · CA